Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11083139 | 0.89 | NPC1 (0.47) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL30422437 | 0.80 | RIPK1 (0.52) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL4795864 | 0.80 | ALDH1A1 (0.45) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL4793575 | 0.80 | ALDH1A1 (0.45) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL16713445 | 0.78 | NPC1 (0.48) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL22743877 | 0.76 | SSTR4 (0.38) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL29442664 | 0.76 | SSTR4 (0.38) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL22743792 | 0.76 | SSTR4 (0.40) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL29350099 | 0.76 | NPC1 (0.65) | RAB9ANPC1POLBPDGFRBPDGFRA | |
| SCHEMBL150476 | 0.76 | NPC1 (0.65) | RAB9ANPC1POLBPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801878-B2 | Quinoline derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2017-10-31 | — | — | US | disclosed |
| US-20160303120-A1 | Quinoline Derivatives as PDE10A Enzyme Inhibitors | H. LUNDBECK A/S (DK) | 2016-10-20 | — | — | US | disclosed |
| US-20150376186-A1 | Quinoline derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-9216986-B1 | Quinoline derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-12-22 | — | — | US | disclosed |
| EP-2794606-A1 | QUINOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. Lundbeck A/S (DK) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092974-A1 | QUINOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376186-A1 | Quinoline derivatives as PDE10A enzyme inhibitors | PDE5A, PDE12, PDE3B | RAB9A 317/4885NPC1 1498/4885POLB 897/4885 |
| US-20160303120-A1 | Quinoline Derivatives as PDE10A Enzyme Inhibitors | PDE5A, PDE3B, PDE12 | RAB9A 295/4885NPC1 1314/4885POLB 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.